3 December 2015 - As part of the previously-announced agreement between Merck & Co., Inc. and Samsung Bioepis Co., Ltd., Merck Canada Inc. announced today that it is preparing to bring to market a diversified portfolio of biosimilar medicines in Canada over the coming years.

For more details, go to: http://www.merck.ca/Assets/News/Merck%20Biosimilar%20Unit%20Launch%20-%20News%20Release%20-%20FINAL.pdf